Trial shows GRI-0621 improved lung function with signs of fibrosis resolution GRI Bio has announced positive topline results from its phase 2a clinical trial evaluating GRI-0621 in idiopathic ...

Barreling toward the end of its cash runway, GRI Bio has shared phase 2a data in idiopathic pulmonary fibrosis (IPF) and made the case for further development of its potentially disease-modifying ...

GRI Bio, Inc. (NASDAQ: GRI) on Wednesday shared topline data from the Phase 2a GRI-0621-IPF-02 trial evaluating GRI-0621 for idiopathic pulmonary fibrosis. IPF is a chronic, progressive lung disease ...

Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used ...

In the ever-evolving world of Indian cinema, numbers speak louder than words. At the heart of every blockbuster, every sleeper hit, and every surprise success is one crucial metric—the Bollywood ...

This guide was reviewed by a Business News Daily editor to ensure it provides comprehensive and accurate information to aid your buying decision. Modern businesses run on data. Companies regularly ...

After three decades spent rising through the ranks of sales and marketing teams at major pharmas, Chris Boulton is taking the top spot at an obesity-focused biotech. Boulton has been named CEO of ...

Doug Wintemute is a staff writer for Forbes Advisor. After completing his master’s in English at York University, he began his writing career in the higher education space. Over the past decade, Doug ...

An inherent principle of publication is that others should be able to replicate and build upon the authors' published claims. A condition of publication in a Nature Portfolio journal is that authors ...